A detailed history of Townsquare Capital LLC transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Townsquare Capital LLC holds 103,223 shares of HALO stock, worth $4.39 Million. This represents 0.07% of its overall portfolio holdings.

Number of Shares
103,223
Previous 59,179 74.43%
Holding current value
$4.39 Million
Previous $3.1 Million 90.61%
% of portfolio
0.07%
Previous 0.04%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$51.3 - $64.42 $2.26 Million - $2.84 Million
44,044 Added 74.43%
103,223 $5.91 Million
Q2 2024

Aug 14, 2024

BUY
$37.81 - $52.4 $354,960 - $491,931
9,388 Added 18.85%
59,179 $3.1 Million
Q1 2024

May 15, 2024

BUY
$33.68 - $41.95 $174,597 - $217,468
5,184 Added 11.62%
49,791 $2.03 Million
Q4 2023

Feb 15, 2024

BUY
$33.32 - $42.1 $14,394 - $18,187
432 Added 0.98%
44,607 $1.65 Million
Q3 2023

Nov 15, 2023

BUY
$36.46 - $44.03 $289,820 - $349,994
7,949 Added 21.94%
44,175 $1.69 Million
Q2 2023

Nov 13, 2023

BUY
$30.28 - $38.74 $681,875 - $872,386
22,519 Added 164.29%
36,226 $1.31 Million
Q1 2023

May 11, 2023

SELL
$32.86 - $55.7 $230 - $389
-7 Reduced 0.05%
13,707 $523,000
Q4 2022

Feb 13, 2023

BUY
$40.06 - $59.44 $269,844 - $400,387
6,736 Added 96.53%
13,714 $780,000
Q3 2022

Nov 10, 2022

SELL
$38.53 - $51.78 $134,084 - $180,194
-3,480 Reduced 33.28%
6,978 $276,000
Q2 2022

Aug 08, 2022

SELL
$37.35 - $48.3 $54,680 - $70,711
-1,464 Reduced 12.28%
10,458 $460,000
Q1 2022

Apr 28, 2022

BUY
$31.97 - $41.06 $220,880 - $283,683
6,909 Added 137.82%
11,922 $475,000
Q4 2021

Feb 11, 2022

SELL
$31.82 - $40.75 $34,524 - $44,213
-1,085 Reduced 17.79%
5,013 $202,000
Q3 2021

Nov 15, 2021

BUY
$38.47 - $46.42 $234,590 - $283,069
6,098 New
6,098 $248,000

Others Institutions Holding HALO

About HALOZYME THERAPEUTICS, INC.


  • Ticker HALO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 139,288,992
  • Market Cap $5.93B
  • Description
  • Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...
More about HALO
Track This Portfolio

Track Townsquare Capital LLC Portfolio

Follow Townsquare Capital LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Townsquare Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Townsquare Capital LLC with notifications on news.